Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

19 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06015880	Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	recruiting	Phase 1	30	National Cancer Institute (NCI)NIH	1	Jul 9, 2026	clinicaltrials
NCT05755087	Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma	recruiting	Phase 1	18	Lapo AlinariOTHER	1	Feb 27, 2026	clinicaltrials